JenniferKimberlyLueMD

PubMed

• Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-...
  Brian Estrella, Mark M Francescone, Yun Kyoung Ryu Tiger, Salvia Jain, Stefan K Barta, Seda Tolu, Ahmed Sawas, Jennifer K Lue, Barbara Pro, Jennifer E Amengual> ;Leukemia & Lymphoma. 2024 Mar 22
• Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
  Gerson, J., Handorf, E., Villa, D., Gerrie, A., Chapani, P., Li, S., Medeiros, L., Wang, M., Cohen, J., Churnetski, M., Hill, B., Sawalha, Y., Hernandez-Ilizaliturri, ...> ;Blood Advances. 2023 Dec 26
• 1 citations
  Retrospective characterization of nodal marginal zone lymphoma.
  Robert Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin,...> ;Blood Advances. 2023 Sep 12
• 3 citations
  TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
  William T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, Alison J Moskowitz, Robert N Stuver, Catherine R Maccaro, Natasha Galasso, Tiffany Chang, Niloufer Khan...> ;Blood Advances. 2023 Sep 12
• Mature T-cell and NK-cell lymphoma involvement of the central nervous system: a single center experience.
  Helen Ma, Enrica Marchi, Owen A O'Connor, Jennifer K Lue> ;Leukemia & Lymphoma. 2023 Dec 1
• The role of B cells in the development, progression, and treatment of lymphomas and solid tumors.
  Jennifer K Lue, Stephanie Downs-Canner, Jayanta Chaudhuri> ;Advances in Immunology. 2022 Jan 1
• 3 citations
  Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
  Luigi Scotto, Cristina Kinahan, Eugene Douglass, Changchun Deng, Maryam Safari, Beatrice Casadei, Enrica Marchi, Jennifer K. Lue, Francesca Montanari, Lorenzo Falchi, ...> ;Molecular Cancer Therapeutics. 2021 Jun 9
• 29 citations
  First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
  Jennifer E Amengual, Jennifer K. Lue, Helen Ma, Renee Lichtenstein, Bijal D. Shah, Serge Cremers, Simon S. Jones, Ahmed Sawas> ;The Oncologist. 2021 Mar 1
• 76 citations
  Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
  Lorenzo Falchi, Helen Ma, Sandra Klein, Jennifer K. Lue, Francesca Montanari, Enrica Marchi, Changchun Deng, Hye A. Kim, Aishling M. Rada, Alice T. Jacob, Cristina Kin...> ;Blood. 2020 Nov 10
• 10 citations
  A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise.
  Jennifer K. Lue, Owen A. O'Connor> ;The Lancet. Haematology. 2020 Nov 1
• 10 citations
  Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond
  Jennifer K. Lue, Owen A. O'Connor, Francesco Bertoni> ;Annals of Lymphoma. 2020 Sep 30
• 2 citations
  Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series.
  Helen Ma, Bin Cheng, Francesca Montanari, Jennifer K. Lue, Changchun Deng, Enrica Marchi, Owen A O' Connor, Ahmed Sawas> ;Therapeutic Advances in Hematology. 2020 Sep 26
• 1 citations
  Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or r...
  Ahmed Sawas, Helen Ma, John Kuruvilla, Jennifer K. Lue, Changchun Deng, Enrica Marchi, Francesca Montanari, Bin Cheng, Kerry J. Savage, Diego Villa, Michael Crump, Jos...> ;Leukemia & Lymphoma. 2020 Jul 28
• 11 citations
  ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic...
  Grzegorz S. Nowakowski, Jun Zhu, Qingyuan Zhang, Joshua Brody, Xiuhua Sun, Joseph Maly, Yuqin Song, Syed Rizvi, Yongping Song, Frederick Lansigan, Hongmei Jing, Junnin...> ;Future Oncology. 2020 Apr 6
• 80 citations
  Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
  Owen A. O'Connor, Lorenzo Falchi, Jennifer K. Lue, Enrica Marchi, Cristina Kinahan, Ahmed Sawas, Changchun Deng, Francesca Montanari, Jennifer E Amengual, Hye A. Kim, ...> ;Blood. 2019 Oct 24
• 51 citations
  Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
  Jennifer K. Lue, Sathyen A. Prabhu, Yuxuan Liu, Yulissa Gonzalez, Akanksha Verma, Prabhjot Mundi, Nebiyu Abshiru, Jeannie M. Camarillo, Swasti Mehta, Emily I. Chen, Ch...> ;Clinical Cancer Research. 2019 Sep 1
• 66 citations
  Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
  James N. Gerson, Elizabeth Handorf, Diego Villa, Alina S. Gerrie, Parv Chapani, Shaoying Li, L. Jeffrey Medeiros, Michael I. Wang, Jonathon B. Cohen, Oscar Calzada, Mi...> ;Journal of Clinical Oncology. 2019 Jan 7
• 69 citations
  Emerging EZH2 Inhibitors and Their Application in Lymphoma
  Jennifer K. Lue, Jennifer E Amengual> ;Current Hematologic Malignancy Reports. 2018 Oct 1
• 11 citations
  Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
  Matko Kalac, Jennifer K. Lue, Emily Lichtenstein, Ithamar Turenne, Celeste Rojas, Jennifer E Amengual, Ahmed Sawas, Changchun Deng, Markus Y. Mapara, Joseph M. Connors...> ;British Journal of Haematology. 2018 Mar 1
• 86 citations
  A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
  Jennifer E Amengual, Renee Lichtenstein, Jennifer K. Lue, Ahmed Sawas, Changchun Deng, Emily Lichtenstein, Karen Khan, Laine Atkins, Aishling M. Rada, Hye A. Kim, Codr...> ;Blood. 2018 Jan 25
• 70 citations
  Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1–2 trial
  Owen A. O'Connor, Jennifer K. Lue, Ahmed Sawas, Jennifer E Amengual, Changchun Deng, Matko Kalac, Lorenzo Falchi, Enrica Marchi, Ithamar Turenne, Renee Lichtenstein, C...> ;The Lancet. Oncology. 2017 Dec 1
• 3 citations
  Therapeutic Options for Aggressive T-Cell Lymphomas.
  Jennifer K. Lue, Anna Kress, Jennifer E Amengual> ;Current Hematologic Malignancy Reports. 2017 Jun 1
• 102 citations
  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
  Daniel J. Landsburg, Marissa K. Falkiewicz, Joseph Maly, Kristie A. Blum, Christina Howlett, Tatyana Feldman, Anthony R. Mato, Brian T. Hill, Shaoying Li, L. Jeffrey M...> ;Journal of Clinical Oncology. 2017 May 5
• 10 citations
  Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
  Jennifer K. Lue, Jennifer E Amengual, Owen A. O'Connor> ;Current Oncology Reports. 2015 Jul 4
• 4 citations
  Carfilzomib for the treatment of multiple myeloma.
  J Lue, S Goel, A Mazumder> ;Drugs of Today. 2013 Mar 1
• Join now to see all

Abstracts/Posters

• Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
  Jennifer Kimberly Lue, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• A basal gene expression signature to predict for synergy of combined EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018